UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number 001-38710

Corteva, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware						82-4979096
(State or other Jurisdiction of Incorporation or Organization)				(I.R.S. Employer Identification No.)
9330 Zionsville Road,	Indianapolis,	Indiana	46268		(833)	267-8382
974 Centre Road,	Wilmington,	Delaware	19805
(Address of Principal Executive Offices) (Zip Code)				(Registrant’s Telephone Number, including area code)

Commission File Number 1-815

EIDP, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware					51-0014090
(State or other Jurisdiction of Incorporation or Organization)				(I.R.S. Employer Identification No.)
9330 Zionsville Road,	Indianapolis,	Indiana	46268		(833)	267-8382
974 Centre Road,	Wilmington,	Delaware	19805
(Address of Principal Executive Offices) (Zip Code)				(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	CTVA	New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act for EIDP, Inc.:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
$3.50 Series Preferred Stock	CTAPrA	New York Stock Exchange
$4.50 Series Preferred Stock	CTAPrB	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

Corteva, Inc.	Yes	x	No	o
EIDP, Inc.	Yes	x	No	o

                             

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 

Corteva, Inc.	Yes	x	No	o
EIDP, Inc.	Yes	x	No	o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Corteva, Inc.	Large Accelerated Filer	x	Accelerated Filer o	Non-Accelerated Filer	o	Smaller reporting company o	Emerging growth company o
EIDP, Inc.	Large Accelerated Filer	o	Accelerated Filer o	Non-Accelerated Filer	x	Smaller reporting company o	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Corteva, Inc.	o
EIDP, Inc.	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Corteva, Inc.	Yes	o	No	x
EIDP, Inc.	Yes	o	No	x

Corteva, Inc. had 696,976,000 shares of common stock, par value $0.01 per share, outstanding at April 25, 2024.

EIDP, Inc. had 200 shares of common stock, par value $0.30 per share, outstanding at April 25, 2024, all of which are held by Corteva, Inc.    

EIDP, Inc. meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.

CORTEVA, Inc.

EIDP, Inc.

Table of Contents

		Page
Explanatory Note
Part I	Financial Information
Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Statements of Operations	3
	Consolidated Statements of Comprehensive Income (Loss)	4
	Consolidated Balance Sheets	5
	Consolidated Statements of Cash Flows	6
	Consolidated Statements of Equity	7
	Notes to the Interim Consolidated Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	39
	Cautionary Statements About Forward-Looking Statements	39
	Recent Developments	40
	Overview	41
	Results of Operations	41
	Recent Accounting Pronouncements	44
	Segment Reviews	44
	Non-GAAP Financial Measures	46
	Liquidity & Capital Resources	49
	Contractual Obligations	51
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	51
Item 4.	Controls and Procedures	52
Part II	Other Information
Item 1.	Legal Proceedings	53
Item 1A.	Risk Factors	55
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	55
Item 3.	Defaults Upon Senior Securities	55
Item 5.	Other Information	55
Item 6.	Exhibits	56
Exhibit Index		56
Signature		57
Consolidated Financial Statements of EIDP, Inc. (Unaudited)		58

1

Explanatory Note

Corteva owns 100% of the outstanding common stock of EIDP (defined below). EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to:

• "Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EIDP);

• "EIDP" refers to EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP excluding its consolidated subsidiaries, as the context may indicate;

• "DowDuPont" refers to DowDuPont Inc. and its subsidiaries prior to the Separation of Corteva (defined below);

• "Historical Dow" refers to The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (defined below);

• "Historical DuPont" refers to EIDP prior to the Internal Reorganization (defined below);

• "Internal Reorganizations" refers to the series of internal reorganization and realignment steps undertaken by Historical DuPont and Historical Dow to realign its business into three groups: agriculture, materials science and specialty products. Refer to the company’s Annual Report on Form 10-K for the year ended December 31, 2023 for further information.

• "Dow Distribution" refers to the separation of DowDuPont's materials science business into a separate and independent public company, on April 1, 2019 by way of a distribution of Dow Inc. through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow Inc.’s common stock;

• "Merger” refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont on August 31, 2017;

• "Dow" refers to Dow Inc. after the Dow Distribution;

• "DuPont" refers to DuPont de Nemours, Inc. after the Separation of Corteva (on June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc.);

• "Separation" or "Separation of Corteva" refers to June 1, 2019, when Corteva, Inc. became an independent, publicly
traded company;

• "Corteva Distribution" refers to the pro rata distribution of all of the then-issued and outstanding shares of Corteva, Inc.'s common stock on June 1, 2019, which was then a wholly-owned subsidiary of DowDuPont, to holders of DowDuPont's common stock as of the close of business on May 24, 2019;

• "Distributions" refers to the Dow Distribution and the Corteva Distribution; and

• “Letter Agreement” refers to the Letter Agreement executed by DuPont and Corteva on June 1, 2019, which sets forth certain additional terms and conditions related to the Separation, including certain limitations on each party’s ability to transfer certain businesses and assets to third parties without assigning certain of such party’s indemnification obligations under the Corteva Separation Agreement to the other party to the transferee of such businesses and assets or meeting certain other alternative conditions.

This Quarterly Report on Form 10-Q is a combined report being filed separately by Corteva, Inc. and EIDP. The information in this Quarterly Report on Form 10-Q is equally applicable to Corteva, Inc. and EIDP, except where otherwise indicated.

The separate EIDP financial statements and footnotes for areas that differ from Corteva, are included within this Quarterly Report on Form 10-Q and begin on page 58. Footnotes of EIDP that are identical to that of Corteva are cross-referenced accordingly.

2

PART I.  FINANCIAL INFORMATION 

Item 1.CONSOLIDATED FINANCIAL STATEMENTS

Corteva, Inc.

Consolidated Statements of Operations (Unaudited)

(In millions, except per share amounts)	Three Months Ended March 31,
	2024		2023
Net sales	$	4,492	$	4,884
Cost of goods sold	2,550		2,771
Research and development expense	332		316
Selling, general and administrative expenses	736		726
Amortization of intangibles	177		160
Restructuring and asset related charges - net	75		33
Other income (expense) - net	(99)		(71)
Interest expense	41		31
Income (loss) from continuing operations before income taxes	482		776
Provision for (benefit from) income taxes on continuing operations	106		169
Income (loss) from continuing operations after income taxes	376		607
Income (loss) from discontinued operations after income taxes	47		(8)
Net income (loss)	423		599
Net income (loss) attributable to noncontrolling interests	4		4
Net income (loss) attributable to Corteva	$	419	$	595
Basic earnings (loss) per share of common stock:
Basic earnings (loss) per share of common stock from continuing operations	$	0.53	$	0.85
Basic earnings (loss) per share of common stock from discontinued operations	0.07		(0.01)
Basic earnings (loss) per share of common stock	$	0.60	$	0.84
Diluted earnings (loss) per share of common stock:
Diluted earnings (loss) per share of common stock from continuing operations	$	0.53	$	0.84
Diluted earnings (loss) per share of common stock from discontinued operations	0.07		(0.01)
Diluted earnings (loss) per share of common stock	$	0.60	$	0.83

See Notes to the Interim Consolidated Financial Statements beginning on page 8.

3

Corteva, Inc.

Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

(In millions)	Three Months Ended March 31,
	2024		2023
Net income (loss)	$	423	$	599
Other comprehensive income (loss) - net of tax:
Cumulative translation adjustments	(304)		134
Adjustments to pension benefit plans	1		2
Adjustments to other benefit plans	(2)		(2)
Unrealized gain (loss) on investments	(22)		—
Derivative instruments	(6)		(67)
Total other comprehensive income (loss)	(333)		67
Comprehensive income (loss)	90		666
Comprehensive income (loss) attributable to noncontrolling interests - net of tax	4		4
Comprehensive income (loss) attributable to Corteva	$	86	$	662

    

See Notes to the Interim Consolidated Financial Statements beginning on page 8.

4

Corteva, Inc.

Consolidated Balance Sheets (Unaudited)

(In millions, except share amounts)	March 31, 2024		December 31, 2023		March 31, 2023
Assets
Current assets
Cash and cash equivalents	$	1,505	$	2,644	$	1,646
Marketable securities	153		98		85
Accounts and notes receivable - net	7,906		5,488		8,678
Inventories	6,183		6,899		6,585
Other current assets	1,416		1,131		1,335
Total current assets	17,163		16,260		18,329
Investment in nonconsolidated affiliates	123		115		87
Property, plant and equipment	9,013		8,956		8,633
Less: Accumulated depreciation	4,807		4,669		4,362
Net property, plant and equipment	4,206		4,287		4,271
Goodwill	10,553		10,605		10,508
Other intangible assets	9,446		9,626		10,137
Deferred income taxes	551		584		508
Other assets	1,583		1,519		1,660
Total Assets	$	43,625	$	42,996	$	45,500
Liabilities and Equity
Current liabilities
Short-term borrowings and finance lease obligations	$	2,148	$	198	$	3,787
Accounts payable	3,606		4,280		3,957
Income taxes payable	311		174		298
Deferred revenue	2,694		3,406		2,712
Accrued and other current liabilities	2,573		2,351		2,477
Total current liabilities	11,332		10,409		13,231
Long-term debt	2,492		2,291		1,241
Other noncurrent liabilities
Deferred income tax liabilities	753		899		1,255
Pension and other post employment benefits - noncurrent	2,453		2,467		2,242
Other noncurrent obligations	1,587		1,651		1,692
Total noncurrent liabilities	7,285		7,308		6,430
Commitments and contingent liabilities
Stockholders’ equity
Common stock, $0.01 par value; 1,666,667,000 shares authorized; issued at March 31, 2024 - 697,800,000; December 31, 2023 - 701,260,000; and March 31, 2023 - 710,678,000	7		7		7
Additional paid-in capital	27,468		27,748		27,844
Retained earnings (accumulated deficit)	302		(41)		487
Accumulated other comprehensive income (loss)	(3,010)		(2,677)		(2,739)
Total Corteva stockholders’ equity	24,767		25,037		25,599
Noncontrolling interests	241		242		240
Total equity	25,008		25,279		25,839
Total Liabilities and Equity	$	43,625	$	42,996	$	45,500

See Notes to the Interim Consolidated Financial Statements beginning on page 8.

5

Corteva, Inc.

Consolidated Statements of Cash Flows (Unaudited)

(In millions)	Three Months Ended March 31,
	2024		2023
Operating activities
Net income (loss)	$	423	$	599
(Income) loss from discontinued operations after income taxes	(47)		8
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities:
Depreciation and amortization	307		287
Provision for (benefit from) deferred income tax	(152)		(85)
Net periodic pension and OPEB (credits) costs	41		36
Pension and OPEB contributions	(53)		(50)
Net (gain) loss on sales of property, businesses, consolidated companies and investments	(5)		1
Restructuring and asset related charges - net	75		33
Other net loss	141		48
Changes in assets and liabilities, net
Accounts and notes receivable	(2,546)		(2,705)
Inventories	618		324
Accounts payable	(615)		(907)
Deferred revenue	(700)		(685)
Other assets and liabilities	(93)		(206)
Cash provided by (used for) operating activities - continuing operations	(2,606)		(3,302)
Cash provided by (used for) operating activities - discontinued operations	(3)		(9)
Cash provided by (used for) operating activities	(2,609)		(3,311)
Investing activities
Capital expenditures	(148)		(151)
Proceeds from sales of property, businesses and consolidated companies - net of cash divested	5		21
Acquisitions of businesses - net of cash acquired	—		(1,463)
Purchases of investments	(132)		—
Proceeds from sales and maturities of investments	7		40
Proceeds from settlement of net investment hedge	—		42
Other investing activities, net	(2)		—
Cash provided by (used for) investing activities	(270)		(1,511)
Financing activities
Net change in borrowings (less than 90 days)	656		3,084
Proceeds from debt	1,675		626
Payments on debt	(190)		(56)
Repurchase of common stock	(252)		(252)
Proceeds from exercise of stock options	8		7
Dividends paid to stockholders	(112)		(107)
Other financing activities, net	(19)		(28)
Cash provided by (used for) financing activities	1,766		3,274
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	(31)		(2)
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(1,144)		(1,550)
Cash, cash equivalents and restricted cash equivalents at beginning of period	3,158		3,618
Cash, cash equivalents and restricted cash equivalents at end of period1	$	2,014	$	2,068

1. See page 14 for reconciliation of cash and cash equivalents and restricted cash equivalents presented in interim Consolidated Balance Sheets to total cash, cash equivalents and restricted cash equivalents presented in the interim Consolidated Statements of Cash Flows.

See Notes to the Interim Consolidated Financial Statements beginning on page 8.

6

Corteva, Inc.

Consolidated Statements of Equity (Unaudited)

(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		Retained Earnings (Accum Deficit)		Accumulated Other Comp Income (Loss)		Non- controlling Interests		Total Equity
2023
Balance at January 1, 2023	$	7	$	27,851	$	250	$	(2,806)	$	239	$	25,541
Net income (loss)					595				4		599
Other comprehensive income (loss)							67				67
Share-based compensation			(14)								(14)
Common dividends ($0.15 per share)					(107)						(107)
Issuance of Corteva stock			7								7
Repurchase of common stock					(252)						(252)
Other - net					1				(3)		(2)
Balance at March 31, 2023	$	7	$	27,844	$	487	$	(2,739)	$	240	$	25,839

(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		Retained Earnings (Accum Deficit)		Accumulated Other Comp Income (Loss)		Non-controlling Interests		Total Equity
2024
Balance at January 1, 2024	$	7	$	27,748	$	(41)	$	(2,677)	$	242	$	25,279
Net income (loss)					419				4		423
Other comprehensive income (loss)							(333)				(333)
Share-based compensation			3		(1)						2
Common dividends ($0.16 per share)			(112)								(112)
Issuance of Corteva stock			8								8
Repurchase of common stock			(178)		(74)						(252)
Other - net			(1)		(1)				(5)		(7)
Balance at March 31, 2024	$	7	$	27,468	$	302	$	(3,010)	$	241	$	25,008

See Notes to the Interim Consolidated Financial Statements beginning on page 8.

7

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Corteva, Inc.

Notes to the Interim Consolidated Financial Statements (Unaudited)

Table of Contents

Note		Page
1	Summary of Significant Accounting Policies	9
2	Recent Accounting Guidance	9
3	Business Combinations	10
4	Revenue	10
5	Restructuring and Asset Related Charges - Net	11
6	Supplementary Information	13
7	Income Taxes	15
8	Earnings Per Share of Common Stock	15
9	Accounts and Notes Receivable - Net	16
10	Inventories	17
11	Other Intangible Assets	17
12	Short-Term Borrowings, Long-Term Debt and Available Credit Facilities	17
13	Commitments and Contingent Liabilities	19
14	Stockholders' Equity	28
15	Pension Plans and Other Post Employment Benefits	30
16	Financial Instruments	31
17	Fair Value Measurements	36
18	Segment Information	36

8

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, collectively referred to as the “2023 Annual Report.” The interim Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained. The interim Consolidated Financial Statements and other financial information included in this Form 10-Q, unless otherwise specified, have been presented to separately show the effects of discontinued operations.

During the fourth quarter of 2023, the company made the decision, which was retrospectively applied, to adjust the presentation of the interim Consolidated Statement of Cash Flows to separately show the cash provided by (used for) operating activities – discontinued operations, which was previously presented within cash provided by (used for) operating activities. See Note 13 – Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information on discontinued operations activities.

Since 2018, Argentina has been considered a hyper-inflationary economy under U.S. GAAP and therefore the U.S. Dollar (“USD”) is the functional currency for our related subsidiaries. Argentina contributes approximately 4 percent and 3 percent to the company's annual net sales and segment operating EBITDA, respectively. The company remeasures net monetary assets utilizing the official Argentine Peso (“Peso”) to USD exchange rate. The ability to draw down Peso cash balances is limited at this time due to government restrictions and market availability of U.S. Dollars. The devaluation of the Peso relative to the USD over the last several years has resulted in the recognition of exchange losses (refer to Note 6 – Supplementary Information, to the interim Consolidated Financial Statements, and Note 7 – Supplementary Information, to the Consolidated Financial Statements, in the company's 2023 Annual Report). The Argentina government has offered USD-denominated bonds to importers, the proceeds from which could be used to pay off outstanding intercompany payables. The company has purchased $125 million of these foreign government bonds as part of its strategy to manage its net monetary asset exposure in Argentina. Refer to the “Debt Securities” section in Note 16 - Financial Instruments, for additional information. As of March 31, 2024, a further 10 percent deterioration in the official Peso to USD exchange rate would not have a significant impact on the USD value of our net monetary assets or pre-tax earnings. The company will continue to assess the implications to our operations and financial reporting.

NOTE 2 - RECENT ACCOUNTING GUIDANCE

Accounting Guidance Issued But Not Adopted as of March 31, 2024

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires that an entity disclose specific categories in the effective tax rate reconciliation as well as reconciling items that meet a quantitative threshold. Further, the ASU requires additional disclosures on income tax expense and taxes paid, net of refunds received, by jurisdiction. The new standard is effective for annual periods beginning after December 15, 2024 on a prospective basis with the option to apply it retrospectively. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced income tax related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU includes amendments that expand the existing reportable segment disclosure requirements and requires disclosure of (i) significant expense categories and amounts by reportable segment as well as the segment’s profit or loss measure(s) that are regularly provided to the chief operating decision maker (the “CODM”) to allocate resources and assess performance; (ii) how the CODM uses each reported segment profit or loss measure to allocate resources and assess performance; (iii) the nature of other segment balances contributing to reported segment profit or loss that are not captured within segment revenues or expenses; and (iv) the title and position of the individual or name of the group or committee identified as the CODM. This guidance requires retrospective application to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced disclosures relating to its reportable segments.

9

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement. The amendments in this ASU are intended to facilitate consistency in the application of accounting guidance upon the formation of entities qualifying as joint ventures. It generally requires the use of business combinations accounting at the joint venture formation date, which would result in the contributed assets/liabilities being revalued to fair value and potentially result in the recognition of goodwill and other intangibles on the joint venture’s financial statements. It does not alter the ongoing accounting for the joint venture’s operations. This guidance is effective for joint ventures with formation dates on or after January 1, 2025. Prospective application is required, with early adoption permitted. Retrospective application can be elected for joint ventures formed before January 1, 2025. The company does not expect the impact of adoption to be material.

NOTE 3 - BUSINESS COMBINATIONS

On March 1, 2023 ("Acquisition Date"), Corteva completed the acquisitions of all the outstanding equity interests in Stoller Group, Inc. (“Stoller”), one of the largest independent companies in the Biologicals industry, and Quorum Vital Investment, S.L. and its affiliates (“Symborg”), an expert in microbiological technologies. The purchase price for Stoller and Symborg was $1,220 million, inclusive of a working capital adjustment, and $370 million, respectively. These acquisitions supplement the crop protection business with additional biological tools that complement evolving farming practices.

The company finalized the purchase price allocation and assessment of the fair value of the assets acquired and liabilities assumed as of the Acquisition Date in the first quarter of 2024. There were no material adjustments recognized during the measurement period. For additional information regarding the acquisition of Stoller and Symborg, see Note 4 - Business Combinations, to the Consolidated Financial Statements, in the company's 2023 Annual Report.

NOTE 4 - REVENUE

Remaining Performance Obligations

Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. The company applies the practical expedient to disclose the transaction price allocated to the remaining performance obligations for only those contracts with an original duration of more than one year. The transaction price allocated to remaining performance obligations with an original duration of more than one year related to material rights granted to customers for contract renewal options were $131 million, $134 million and $126 million at March 31, 2024, December 31, 2023 and March 31, 2023, respectively. The company expects revenue to be recognized for the remaining performance obligations evenly over the period of one year to six years.

Contract Balances

Contract liabilities primarily reflect deferred revenue from prepayments under contracts with customers where the company receives advance payments for products to be delivered in future periods. Corteva classifies deferred revenue as current or noncurrent based on the timing of when the company expects to recognize revenue. Contract assets primarily include amounts related to conditional rights to consideration for completed performance not yet invoiced. Accounts receivable are recorded when the right to consideration becomes unconditional.

Contract Balances	March 31, 2024		December 31, 2023		March 31, 2023
(In millions)
Accounts and notes receivable - trade1	$	6,760	$	4,329	$	7,334
Contract assets - current2	28		27		26
Contract assets - noncurrent3	67		67		63
Deferred revenue - current	2,694		3,406		2,712
Deferred revenue - noncurrent4	104		108		103

1.Included in accounts and notes receivable - net in the interim Consolidated Balance Sheets.

2.Included in other current assets in the interim Consolidated Balance Sheets.

3.Included in other assets in the interim Consolidated Balance Sheets.

4.Included in other noncurrent obligations in the interim Consolidated Balance Sheets.

Revenue recognized during the three months ended March 31, 2024 and 2023 from amounts included in deferred revenue at the beginning of the period was $1,205 million and $1,201 million, respectively.

10

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Disaggregation of Revenue

Corteva's operations are classified into two reportable segments: Seed and Crop Protection. The company disaggregates its revenue by major product line and geographic region, as the company believes it best depicts the nature, amount and timing of its revenue and cash flows. Net sales by major product line are included below:

	Three Months Ended March 31,
(In millions)	2024		2023
Corn	$	2,087	$	1,979
Soybean	292		269
Other oilseeds	245		301
Other	127		146
Seed	2,751		2,695
Herbicides	886		1,242
Insecticides	373		409
Fungicides	295		359
Other	187		179
Crop Protection	1,741		2,189
Total	$	4,492	$	4,884

Sales are attributed to geographic regions based on customer location. Net sales by geographic region and segment are included below:

Seed	Three Months Ended March 31,
(In millions)	2024		2023
North America1	$	1,471	$	1,323
EMEA2	918		1,012
Latin America	271		259
Asia Pacific	91		101
Total	$	2,751	$	2,695

Crop Protection	Three Months Ended March 31,
(In millions)	2024		2023
North America1	$	616	$	879
EMEA2	670		801
Latin America	244		293
Asia Pacific	211		216
Total	$	1,741	$	2,189

1.Represents U.S. & Canada.

2.Europe, Middle East and Africa ("EMEA").

NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET

Crop Protection Operations Strategy Restructuring Program

On November 5, 2023, management of the company approved a plan to further optimize its Crop Protection network of manufacturing and external partners (the "Crop Protection Operations Strategy Restructuring Program"). The plan includes the exit of the company’s production activities at its site in Pittsburg, California, as well as ceasing operations in select manufacturing lines at other locations.

The company expects to record aggregate pre-tax restructuring and asset related charges of $410 million to $460 million, comprised of $70 million to $90 million of severance and related benefit costs, $320 million to $340 million of asset-related and impairment charges and $20 million to $30 million of costs related to contract terminations. Reductions in workforce are

11

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

subject to local regulatory requirements. Through the first quarter of 2024, the company recorded net pre-tax restructuring and asset related charges of $284 million, comprised of $14 million of severance and related benefit costs, $267 million of asset-related and impairment charges and $3 million of costs related to contract terminations. The pre-tax restructuring and asset related charges noted above includes charges relating to spare parts write-offs recognized during the fourth quarter of 2023, which impacted the crop protection segment, and were included in cost of goods sold, in the company’s Consolidated Statement of Operations for the year ended December 31, 2023. See Note 23 – Segment Information, to the Consolidated Financial Statements, in the company’s 2023 Annual Report for additional information.

Future cash payments related to these charges are anticipated to be $90 million to $120 million, which primarily relate to the payment of severance and related benefits and contract terminations. Through the first quarter of 2024, the company paid $3 million associated with these charges. The restructuring actions associated with these charges are expected to be substantially complete in 2024.

The following table is a summary of charges incurred related to the Crop Protection Operations Strategy Restructuring Program for the three months ended March 31, 2024.

(In millions)	Three Months Ended March 31, 2024
Severance and related benefit costs1	$	14
Asset related charges2	41
Total restructuring and asset related charges - net	$	55

1.Reflects corporate-related charges.

2.Reflects charges associated with the crop protection segment.

A reconciliation of the December 31, 2023 to the March 31, 2024 liability balances related to the Crop Protection Operations Strategy Restructuring Program is summarized below:

(In millions)	Severance and Related Benefit Costs		Asset Related		Total
Balance at December 31, 2023	$	—	$	—	$	—
Charges to income from continuing operations	14		41		55
Asset write-offs	—		(41)		(41)
Balance at March 31, 2024	$	14	$	—	$	14

2022 Restructuring Actions

In connection with the company’s shift to a global business unit model during 2022, the company assessed its business priorities and operational structure to maximize the customer experience and deliver on growth and earnings potential. As a result of this assessment, the company committed to restructuring actions during the second quarter of 2022, which included the company’s separate announcement to withdraw from Russia (“Russia Exit”) (collectively the “2022 Restructuring Actions”). Through the first quarter of 2024, the company recorded net pre-tax restructuring and other charges of $373 million inception-to-date under the 2022 Restructuring Actions, consisting of $131 million of severance and related benefit costs, $116 million of asset related charges, $67 million of costs related to contract terminations (including early lease terminations) and $59 million of other charges. The company does not anticipate any additional material charges from the 2022 Restructuring Actions as actions associated with this charge are substantially complete.

Cash payments related to these charges are anticipated to be up to $210 million, of which approximately $160 million has been paid through March 31, 2024, and primarily relate to the payment of severance and related benefits, contract terminations and other charges.

The total net pre-tax restructuring and other charges recognized through the three months ended March 31, 2024 included $53 million associated with the Russia Exit. The Russia Exit net pre-tax restructuring charges consisted of $6 million of severance and related benefit costs, $6 million of asset related charges, and $30 million of costs related to contract terminations (including early lease terminations). Other pre-tax charges associated with the Russia Exit were recorded to cost of goods sold and other income (expense) – net in the Consolidated Statement of Operations, relating to inventory write-offs of $3 million and settlement costs of $8 million, respectively.

12

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table is a summary of charges incurred related to the 2022 Restructuring Actions for the three months ended March 31, 2023.

(In millions)	Three Months Ended March 31, 2023
Severance and related benefit costs1	$	4
Asset related charges2	7
Total restructuring and asset related charges - net3	$	11

1.Reflects corporate-related charges.

2.Reflects charges of $6 million and $1 million associated with the seed and crop protection segment, respectively.

3.This amount excludes other pre-tax charges recorded during the three months ended March 31, 2023 impacting the Seed segment included in cost of goods sold and other income (expense) – net, in the company’s interim Consolidated Statement of Operations, relating to inventory write-offs and a loss on the sale of the company's interest in an equity investment. See Note 18 - Segment Information, to the interim Consolidated Financial Statements, for additional information.

A reconciliation of the December 31, 2023 to the March 31, 2024 liability balances related to the 2022 Restructuring Actions is summarized below:

(In millions)	Severance and Related Benefit Costs		Asset Related		Contract Termination1		Total
Balance at December 31, 2023	$	48	$	1	$	9	$	58
Payments	(8)		—		—		(8)
Balance at March 31, 2024	$	40	$	1	$	9	$	50

1.The liability for contract terminations includes lease obligations.

Other Asset Related Charges

The company recognized charges of $20 million and $16 million for the three months ended March 31, 2024 and 2023 respectively, in restructuring and asset related charges - net, in the interim Consolidated Statement of Operations, from non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

NOTE 6 - SUPPLEMENTARY INFORMATION

Other Income (Expense) - Net	Three Months Ended March 31,
(In millions)	2024		2023
Interest income	$	35	$	40
Equity in earnings (losses) of affiliates - net	8		3
Net gain (loss) on sales of businesses and other assets	4		(1)
Net exchange gains (losses)1	(59)		(36)
Non-operating pension and other post employment benefit credit (costs)2	(36)		(31)
Miscellaneous income (expenses) - net3	(51)		(46)
Other income (expense) - net	$	(99)	$	(71)

1.Includes net pre-tax exchange gains (losses) of $(10) million and $(21) million associated with the devaluation of the Argentine peso for the three months ended March 31, 2024, and 2023, respectively.

2.Includes non-service related components of net periodic benefit credits (costs) (interest cost, expected return on plan assets, amortization of unrecognized gain (loss), amortization of prior service benefit and settlement gain (loss)).

3.Includes estimated settlement reserves and other items. The three months ended March 31, 2024 also includes the recognition of an indemnification payment negotiated with prior Stoller owners and tax indemnification adjustments related to changes in indemnification balances as a result of the application of the terms of the Tax Matters Agreement between Corteva and Dow and/or DuPont. The three months ended March 31, 2023 also includes gains on the sale of assets and a loss on the sale of the company’s interest in an equity investment.

13

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the U.S., whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the interim Consolidated Statements of Operations.

(In millions)	Three Months Ended March 31,
	2024		2023
Subsidiary Monetary Position Gain (Loss)
Pre-tax exchange gain (loss)	$	23	$	(30)
Local tax (expenses) benefits	(10)		9
Net after-tax impact from subsidiary exchange gain (loss)	$	13	$	(21)
Hedging Program Gain (Loss)
Pre-tax exchange gain (loss)	$	(82)	$	(6)
Tax (expenses) benefits	17		2
Net after-tax impact from hedging program exchange gain (loss)	$	(65)	$	(4)
Total Exchange Gain (Loss)
Pre-tax exchange gain (loss)	$	(59)	$	(36)
Tax (expenses) benefits	7		11
Net after-tax exchange gain (loss)	$	(52)	$	(25)
Non-Controlling Interest Adjustment	1		—
Net after-tax exchange gain (loss) attributable to Corteva	$	(51)	$	(25)

Cash, cash equivalents and restricted cash equivalents

The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents presented in the interim Consolidated Balance Sheets to the total cash, cash equivalents and restricted cash equivalents presented in the interim Consolidated Statements of Cash Flows. Corteva classifies restricted cash equivalents as current or noncurrent based on the nature of the restrictions, which are included in other current assets and other assets, respectively, in the interim Consolidated Balance Sheets.

(In millions)	March 31, 2024		December 31, 2023		March 31, 2023
Cash and cash equivalents	$	1,505	$	2,644	$	1,646
Restricted cash equivalents	509		514		422
Total cash, cash equivalents and restricted cash equivalents	$	2,014	$	3,158	$	2,068

Restricted cash equivalents primarily relates to a trust funded by EIDP for cash obligations under certain non-qualified benefit and deferred compensation plans due to the Merger, which was a change in control event, and contributions to escrow accounts established for the settlement of certain legal matters and the settlement of legacy PFAS matters and the associated qualified spend. All of the company's restricted cash equivalents are classified as current as of March 31, 2024, December 31, 2023 and March 31, 2023, except for the contributions to the escrow account established for the settlement of legacy PFAS matters and the associated qualified spend, which was classified as noncurrent at March 31, 2023.

Accounts payable

At March 31, 2024, December 31, 2023 and March 31, 2023, accounts payable was $3,606 million, $4,280 million and $3,957 million, respectively, which includes accounts payable - trade of $1,982 million, $2,952 million and $2,315 million, respectively. Included in accounts payable – trade was seed grower compensation of approximately $285 million, $560 million and $185 million, respectively, which is measured at fair value using level 2 inputs for each period presented.

14

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 7 - INCOME TAXES

The effective tax rate for the three months ended March 31, 2024, and 2023 was 22.0 percent and 21.8 percent, respectively.

During the three months ended March 31, 2024 and 2023, the company recognized $6 million and $12 million, respectively, of net tax benefits for income taxes on continuing operations associated with changes in deferred taxes and accruals for certain prior year tax positions in various jurisdictions as well as from stock-based compensation.

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of the program, which resides in the U.S., is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions, which can drive material impacts on the company's effective tax rate. For further discussion of pre-tax and after-tax impacts of the company's foreign currency hedging program and net monetary asset programs, refer to Note 6 - Supplementary Information.

NOTE 8 - EARNINGS PER SHARE OF COMMON STOCK

The following tables provide earnings per share calculations for the periods indicated below:

Net Income (Loss) for Earnings (Loss) Per Share Calculations - Basic and Diluted	Three Months Ended March 31,
(In millions)	2024		2023
Income (loss) from continuing operations after income taxes	$	376	$	607
Net income (loss) attributable to continuing operations noncontrolling interests	4		4
Income (loss) from continuing operations available to Corteva common stockholders	372		603
Income (loss) from discontinued operations available to Corteva common stockholders	47		(8)
Net income (loss) available to common stockholders	$	419	$	595

Earnings (Loss) Per Share Calculations - Basic	Three Months Ended March 31,
(Dollars per share)	2024		2023
Earnings (loss) per share of common stock from continuing operations	$	0.53	$	0.85
Earnings (loss) per share of common stock from discontinued operations	0.07		(0.01)
Earnings (loss) per share of common stock	$	0.60	$	0.84

Earnings (Loss) Per Share Calculations - Diluted	Three Months Ended March 31,
(Dollars per share)	2024		2023
Earnings (loss) per share of common stock from continuing operations	$	0.53	$	0.84
Earnings (loss) per share of common stock from discontinued operations	0.07		(0.01)
Earnings (loss) per share of common stock	$	0.60	$	0.83

Share Count Information	Three Months Ended March 31,
(Shares in millions)	2024	2023
Weighted-average common shares - basic	700.4	712.9
Plus dilutive effect of equity compensation plans1	2.4	3.3
Weighted-average common shares - diluted	702.8	716.2
Potential shares of common stock excluded from EPS calculations2	3.6	2.7

1.Diluted earnings (loss) per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

2.These outstanding potential shares of common stock relating to stock options, restricted stock units and performance-based restricted stock units were excluded from the calculation of diluted earnings (loss) per share because (i) the effect of including them would have been anti-dilutive; and (ii) the performance metrics have not yet been achieved for the outstanding potential shares relating to performance-based restricted stock units, which are deemed to be contingently issuable.

15

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE - NET

(In millions)	March 31, 2024		December 31, 2023		March 31, 2023
Accounts receivable – trade1	$	6,320	$	4,210	$	6,883
Notes receivable – trade1,2	440		119		451
Other3	1,146		1,159		1,344
Total accounts and notes receivable - net	$	7,906	$	5,488	$	8,678

1.Accounts and notes receivable - trade are net of allowances of $188 million, $205 million and $207 million at March 31, 2024, December 31, 2023 and March 31, 2023, respectively.

2.Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed and chemical products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of March 31, 2024, December 31, 2023 and March 31, 2023 there were no significant impairments related to current loan agreements.

3.Other includes receivables in relation to indemnification assets, value added tax, general sales tax and other taxes. No individual group represents more than 5 percent of total current assets. In addition, Other includes amounts due from nonconsolidated affiliates of $125 million, $131 million and $137 million as of March 31, 2024, December 31, 2023 and March 31, 2023, respectively.

Accounts and notes receivable are carried at the expected amount to be collected, which approximates fair value. The company establishes the allowance for doubtful receivables using a loss-rate method where the loss rate is developed using past events, historical experience, current conditions and forecasts that affect the collectability of the financial assets.

The following table summarizes changes in the allowance for doubtful receivables for the three months ended March 31, 2024 and 2023:

(In millions)
2023
Balance at December 31, 2022	$	194
Net provision for credit losses	10
Other - net of write-offs charged against allowance	3
Balance at March 31, 2023	$	207
2024
Balance at December 31, 2023	$	205
Net provision for credit losses	13
Other - net of write-offs charged against allowance	(30)
Balance at March 31, 2024	$	188

The company enters into various factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds. These financing arrangements result in a transfer of the company's receivables and risks to the third-party. As these transfers qualify as true sales under the applicable accounting guidance, the receivables are derecognized from the interim Consolidated Balance Sheets upon transfer, and the company receives a payment for the receivables from the third-party within a mutually agreed upon time period. For arrangements involving an element of recourse, which is typically provided through a guarantee of accounts in the event of customer default, the guarantee obligation is measured using market data from similar transactions and reported as a current liability in the interim Consolidated Balance Sheets.

Trade receivables sold under these agreements were $18 million and $8 million for the three months ended March 31, 2024 and 2023, respectively. The trade receivables sold that remained outstanding under these agreements which include an element of recourse as of March 31, 2024, December 31, 2023 and March 31, 2023 were $4 million, $2 million and $19 million, respectively. The net proceeds received are included in cash provided by (used for) operating activities in the interim Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in other income (expense) - net, in the interim Consolidated Statements of Operations. The loss on sale of receivables for the three months ended March 31, 2024 and 2023 was not material. See Note 13 - Commitments and Contingent Liabilities for additional information on the company’s guarantees.

16

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 10 - INVENTORIES

(In millions)	March 31, 2024		December 31, 2023		March 31, 2023
Finished products	$	3,284	$	3,273	$	3,650
Semi-finished products	2,206		2,775		2,023
Raw materials and supplies	693		851		912
Total inventories	$	6,183	$	6,899	$	6,585

NOTE 11 - OTHER INTANGIBLE ASSETS

Other Intangibles Assets

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: 

(In millions)	March 31, 2024						December 31, 2023						March 31, 2023
	Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Intangible assets subject to amortization (finite-lived):
Germplasm	$	6,291	$	(1,145)	$	5,146	$	6,291	$	(1,081)	$	5,210	$	6,291	$	(890)	$	5,401
Customer-related	2,421		(766)		1,655		2,427		(734)		1,693		2,407		(617)		1,790
Developed technology	1,846		(1,050)		796		1,849		(1,004)		845		1,845		(868)		977
Trademarks/trade names	2,111		(361)		1,750		2,111		(339)		1,772		2,107		(271)		1,836
Other1	395		(301)		94		395		(294)		101		395		(276)		119
Total other intangible assets with finite lives	13,064		(3,623)		9,441		13,073		(3,452)		9,621		13,045		(2,922)		10,123
Intangible assets not subject to amortization (indefinite-lived):
IPR&D	5		—		5		5		—		5		14		—		14
Total other intangible assets with     indefinite lives	5		—		5		5		—		5		14		—		14
Total other intangible assets	$	13,069	$	(3,623)	$	9,446	$	13,078	$	(3,452)	$	9,626	$	13,059	$	(2,922)	$	10,137

1.Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $177 million and $160 million for the three months ended March 31, 2024 and 2023, respectively. The current estimated aggregate pre-tax amortization expense from continuing operations for the remainder of 2024 and each of the next five years is approximately $509 million, $646 million, $635 million, $575 million, $554 million and $531 million, respectively.

NOTE 12 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

The following tables summarize Corteva's short-term borrowings and finance lease obligations and long-term debt:

Short-term borrowings and finance lease obligations
(In millions)	March 31, 2024		December 31, 2023		March 31, 2023
Commercial paper	$	1,981	$	—	$	2,680
364-Day Revolving Credit Facility	—		—		1,000
Other loans - various currencies	166		1		57
Long-term debt payable within one year	—		196		49
Finance lease obligations payable within one year	1		1		1
Total short-term borrowings and finance lease obligations	$	2,148	$	198	$	3,787

17

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Long-term debt
(In millions)	March 31, 2024				December 31, 2023				March 31, 2023
	Amount		Weighted Average Rate		Amount		Weighted Average Rate		Amount		Weighted Average Rate
Promissory notes and debentures:
Maturing in 2025	$	500	1.70	%	$	500	1.70	%	$	500	1.70	%
Maturing in 2026	600		4.50	%	600		4.50	%	—
Maturing in 2030	500		2.30	%	500		2.30	%	500		2.30	%
Maturing in 2033	600		4.80	%	600		4.80	%	—
Other loans:
Foreign currency loans, various rates and maturities	200		12.70	%	196		14.80	%	187		14.80	%
Medium-term notes, varying maturities through 2041	106		5.28	%	106		5.34	%